Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials

Critical Care Medicine

Volumn 38, Issue 11, 2010, Pages 2229-2241

  Kopterides, Petros ^a   Siempos, Ilias I ^a   Tsangaris, Iraklis ^a   Tsantes, Argirios ^a   Armaganidis, Apostolos ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Biomarker; critically ill; procalcitonin; protocol; resistance; sepsis

Indexed keywords

PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ALGORITHM; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BIBLIOGRAPHIC DATABASE; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INFECTION RATE; INTENSIVE CARE UNIT; LENGTH OF STAY; MANTEL HAENSZEL TEST; MEDLINE; META ANALYSIS; MORTALITY; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SEPSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADULT; BLOOD; INTENSIVE CARE; METHODOLOGY; NEWBORN; NEWBORN INTENSIVE CARE; RECURRENT DISEASE; REVIEW;

ADULT; ALGORITHMS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; CALCITONIN; CRITICAL CARE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS; INTENSIVE CARE UNITS, NEONATAL; PROTEIN PRECURSORS; RECURRENCE; SEPSIS;

EID: 78049418360     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181f17bf9     Document Type: Review

References (50)

1. Vincent JL, Rello J, Marshall J, et al; EPIC II Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-2329
2. Gikas A, Pediaditis J, Papadakis JA, et al; Greek Infection Control Network: Prevalence study of hospital-acquired infections in 14 Greek hospitals: Planning from the local to the national surveillance level. J Hosp Infect 2002;50:269-275
3. Dombrovskiy VY, Martin AA, Sunderram J, et al: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007;35:1244-1250
4. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554
5. Bone R, Balk R, Cerra F, et al; The ACCP/SCCM Consensus Conference Committee American College of Chest Physicians/Society of Critical Care Medicine: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644-1655
6. Kumar A, Roberts D, Wood KE, et al: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-1596
7. Livermore DM: Minimising antibiotic resistance. Lancet Infect Dis 2005;5:450-459
8. Pierrakos C, Vincent JL: Sepsis biomarkers: A review. Crit Care 2010;14:R15
9. Becker KL, Nylén ES, White JC, et al: Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: A journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-1525
10. Uzzan B, Cohen R, Nicolas P, et al: Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med 2006;34:1996-2003
11. Simon L, Gauvin F, Amre DK, et al: Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clin Infect Dis 2004;39:206-217
12. Tang BM, Eslick GD, Craig JC, et al: Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217
13. Dellinger RP, Levy MM, Carlet JM, et al: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; N36:296-327
14. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group: Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003;290:2588-2598
15. Schuetz P, Christ-Crain M, Thomann R, et al; ProHOSP Study Group: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA 2009;302:1059-1066
16. Briel M, Schuetz P, Mueller B, et al: Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000-2007
17. Stolz D, Christ-Crain M, Bingisser R, et al: Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007;131:9-19
18. Christ-Crain M, Stolz D, Bingisser R, et al: Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006;174:84-93
19. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-607
20. Moher D, Liberati A, Tetzlaff J, et al: PRISMA Group: Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med 2009;151:264-269
21. Rosmarakis ES, Soteriades ES, Vergidis PI, et al: From conference abstract to full paper: Differences between data presented in conferences and journals. FASEB J 2005;19:673-680
22. Jüni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-46
23. Higgins J P T, Altman DG: Assessing risk of bias in included studies In: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. Higgins JPT, Green S (Eds). The Cochrane Collaboration; updated February 2008. Available at: http://www.cochrane-handbook.org. Accessed February 15, 2010
24. Higgins JP, Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558
25. Higgins JP, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560
26. Hozo SP, Djulbegovic B, Hozo I: Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13
27. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748
28. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188
29. Ioannidis JP, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey. CMAJ 2007;176:1091-1096
30. Deeks JJ, Higgins J P T, Altman DG: Analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.0. Higgins JPT, Green S (Eds). The Cochrane Collaboration; updated February 2008. Available at: http://www.cochrane-handbook.org. Accessed February 15, 2010
31. Bouadma L, Luyt CE, Tubach F, et al; PRORATA trial group: Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010;375:463-474
32. Stolz D, Smyrnios N, Eggimann P, et al: Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: A randomised study. Eur Respir J 2009;34:1364-1375
33. Hochreiter M, Köhler T, Schweiger AM, et al: Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit Care 2009;13:R83
34. Schroeder S, Hochreiter M, Koehler T, et al: Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: Results of a prospective randomized study. Langenbecks Arch Surg 2009;394:221-226
35. Nobre V, Harbarth S, Graf JD, et al: Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008;177:498-505
36. Svoboda P, Kantorová I, Scheer P, et al: Can procalcitonin help us in timing of reintervention in septic patients after multiple trauma or major surgery? Hepatogastroenterology 2007;54:359-363
37. Stocker M, Fontana M, El Helou S, et al: Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: Prospective randomized intervention trial. Neonatology 2010;97:165-174
38. Roberts JA, Kruger P, Paterson DL, et al: Antibiotic resistance-What's dosing got to do with it? Crit Care Med 2008;36:2433-2440
39. Rubenfeld GD, Angus DC, Pinsky MR, et al: Outcomes research in critical care: results of the American Thoracic Society Critical Care Assembly Workshop on Outcomes Research The Members of the Outcomes Research Workshop. Am J Respir Crit Care Med 1999;160:358-367
40. Siempos II, Ntaidou TK, Falagas ME: Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: A meta-analysis of randomized controlled trials. Crit Care Med 2010;38:954-962
41. Micek ST, Ward S, Fraser VJ, et al: A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791-1799
42. Louie RF, Tang Z, Albertson TE, et al: Multiplex polymerase chain reaction detection enhancement of bacteremia and fungemia. Crit Care Med 2008;36:1487-1492
43. Giamarellos-Bourboulis EJ, Grecka P, Poulakou G, et al: Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clin Infect Dis 2001;32:1718-1725
44. Kollef MH: Will procalcitonin reduce antibiotic use in intensive care? Lancet 2010;375:435-436
45. Tsangaris I, Plachouras D, Kavatha D, et al: Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis 2009;9:213
46. Reade MC, Delaney A, Bailey MJ, et al: Prospective meta-analysis using individual patient data in intensive care medicine. Intensive Care Med 2010;36:11-21
47. The Procalcitonin and Survival Study (PASS). Available at: http://www.clinicaltrials. gov/ct2/show/NCT00271752. Accessed April 15, 2010
48. Placebo controlled trial of sodium selenite and procalcitonin guided antimicrobial therapy in severe sepsis (SISPCT). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00832039. Accessed April 15, 2010
49. Safety and efficacy of procalcitonin guided antibiotic therapy in adult intensive care units (ICU's) (SAPS). Available at: http://www.clinicaltrials. gov/ct2/show/NCT01139489. Accessed April 15, 2010
50. Procalcitonin level to discontinue antibiotics on ICU patients with no obvious site of infection. Available at: http://www.clinicaltrials. gov/ct2/show/NCT00407147. Accessed April 15, 2010